Company news

Alkermes plc news in 2020

Alkermes plc's news releases, calls and decks from 2020, newest first.

View company

FDA Accepts Alkermes' Resubmission of New Drug Application for ALKS 3831

December 28, 2020

Alkermes Announces Strategic Value Enhancement Plan and Continued Board Refreshment

December 9, 2020

Alkermes Receives FDA Complete Response Letter Related to ALKS 3831 Manufacturing Records Review

November 16, 2020

Alkermes Presents New Data on ALKS 4230 at Society for Immunotherapy of Cancer's (SITC) 35th Anniversary Annual Meeting

November 8, 2020

Alkermes Reschedules Third Quarter 2020 Financial Results Conference Call to 10: 30 a.m. ET

October 28, 2020

Alkermes to Host Conference Call to Discuss Third Quarter 2020 Financial Results

October 21, 2020

Alkermes Announces Posting of Briefing Documents for FDA Advisory Committee Meeting on ALKS 3831

October 6, 2020

Alkermes Presents New Psychiatry Data at Psych Congress 2020 Virtual Experience

September 13, 2020

Virtual FDA Advisory Committee Meeting to Review New Drug Application for ALKS 3831 for Treatment of Schizophrenia and Bipolar I Disorder Tentatively Scheduled for Oct. 9, 2020

August 20, 2020

Alkermes Initiates Phase 2 Study Designed to Evaluate Clinical and Immunologic Activity of ALKS 4230 on Tumor Microenvironment in Patients with Advanced Solid Tumors

August 18, 2020

Alkermes plc Reports Second Quarter 2020 Financial Results and Issues 2020 Financial Expectations

July 28, 2020

Alkermes to Host Conference Call to Discuss Second Quarter 2020 Financial Results

July 21, 2020

Alkermes Announces Launch of 3rd Annual Alkermes Pathways Research Awards® Program

June 28, 2020

Alkermes Awards COVID-19 Relief Fund Grants to 10 Innovative Programs Designed to Address Challenges for Patient Communities

June 23, 2020

Alkermes Announces Expansion of Patient Services and Provider Network to Support Uninterrupted Access to ARISTADA® and VIVITROL® During COVID-19 Crisis

May 10, 2020

Alkermes Launches COVID-19 Relief Fund to Support Innovative Programs Helping Vulnerable Patient Communities

May 3, 2020

Alkermes Plc Reports First Quarter 2020 Financial Results and Provides COVID-19 Related Business Update

April 28, 2020

Alkermes Announces Publication of Preclinical Data for ALKS 4230 in the Journal for ImmunoTherapy of Cancer

April 21, 2020

Alkermes Plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2019 and Provides Financial Expectations for 2020

February 12, 2020

Alkermes to Host Conference Call to Discuss Fourth Quarter and Year-End 2019 Financial Results

February 5, 2020

Alkermes Announces U.S. Food and Drug Administration Acceptance of ALKS 3831 New Drug Application for Treatment of Schizophrenia and Bipolar I Disorder

January 27, 2020

Decks in 2020